City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John ...
Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting ...
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay ...
Repare Therapeutics pauses gynecologic cancer drugs lunresertib & camonsertib, shifts focus to early-stage assets RP-1664 & RP-3467 amid cost-cutting measures.
IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now it's ...
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, it's unveiling new results ...
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 ...
Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The ...
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...
Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback